There’s a federal regulation coming into full effect on November 27, 2026, that could impact how you run your medical practice, aesthetic clinic, or med spa. If you keep prescription medications on-site—whether for injections, procedures, or patient sales—you need to understand the Drug Supply Chain Security Act (DSCSA) and what it means for your day-to-day operations.

This isn’t about adding red tape. It’s about protecting patients from counterfeit and contaminated drugs. But it does mean new tracking requirements, and the clock is ticking.

Let’s walk through what you need to know and how to prepare without disrupting your practice.

Continue reading Is Your Medical Practice Ready for 2026? A Practical Guide to DSCSA Compliance →

Essential Guidance for Pharmaceutical Companies Adapting to New Serialization Requirements

---

Introduction: A Pivotal Moment for Pharmaceutical Identification

The pharmaceutical industry stands at a crossroads. Two major regulatory shifts are converging to reshape how drug products are identified, tracked, and verified throughout the distribution network. Understanding these changes and implementing compliant systems is no longer optional—it’s a fundamental requirement for market access.

The Drug Supply Chain Security Act’s enhanced traceability mandates have moved from planning phase to full operational reality. At the same time, the Food and Drug Administration is overhauling the National Drug Code structure, expanding it from its traditional format to accommodate future growth. These parallel transformations create both technical challenges and opportunities for companies willing to invest in robust identification infrastructure.

This article provides practical guidance for pharmaceutical manufacturers navigating this transition, with specific focus on how to properly construct Global Trade Item Numbers that meet both current compliance requirements and prepare for the expanded NDC format coming in the next several years.

Continue reading Navigating GTIN Standards for NDC Compliance: Your 2025-2026 Roadmap →

Iowa lawmakers are tackling a $20 billion blind spot in pharmaceutical regulation—and the implications reach far beyond state borders.

---

A Compliance Revolution Brewing in the Heartland

When most people think about pharmaceutical regulation, they picture traditional pharmacies with their familiar orange prescription bottles and white-coated pharmacists. But there’s a massive segment of the healthcare industry dispensing prescription medications with virtually no oversight: medical spas and wellness clinics.

Iowa is about to change that equation dramatically.

Continue reading Iowa’s Med Spa Compliance Revolution: What HSB 591 Means for You →